生物标志物靶向治疗非小细胞肺癌：现状与展望。
Biomarker-Targeted Therapies in Non-Small Cell Lung Cancer: Current Status and Perspectives.
机构信息
Department of Thoracic Surgery, Suining Central Hospital, Suining 629099, China.
Institute of Surgery, Graduate School, Chengdu University of TCM, Chengdu 610075, China.
出版信息
Cells. 2022 Oct 12;11(20):3200. doi: 10.3390/cells11203200.
Non-small-cell lung cancer (NSCLC) is one of the most common malignancies and the leading causes of cancer-related death worldwide. Despite many therapeutic advances in the past decade, NSCLC remains an incurable disease for the majority of patients. Molecular targeted therapies and immunotherapies have significantly improved the prognosis of NSCLC. However, the vast majority of advanced NSCLC develop resistance to current therapies and eventually progress. In this review, we discuss current and potential therapies for NSCLC, focusing on targeted therapies and immunotherapies. We highlight the future role of metabolic therapies and combination therapies in NSCLC.
非小细胞肺癌（NSCLC）是最常见的恶性肿瘤之一，也是全球癌症相关死亡的主要原因。尽管在过去十年中取得了许多治疗进展，但 NSCLC 仍然是大多数患者无法治愈的疾病。分子靶向治疗和免疫疗法显著改善了 NSCLC 的预后。然而，绝大多数晚期 NSCLC 对当前的治疗方法产生耐药性，最终进展。在这篇综述中，我们讨论了 NSCLC 的当前和潜在治疗方法，重点讨论了靶向治疗和免疫治疗。我们强调了代谢治疗和联合治疗在 NSCLC 中的未来作用。
Zotero 插件